Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
The Company's portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Company Growth (employees)
Type
Public
HQ
Foster City, US
Founded
1987
Size (employees)
9,000 (est)+13%
Website
gilead.com
Gilead Sciences was founded in 1987 and is headquartered in Foster City, US

Key People at Gilead Sciences

John Milligan

John Milligan

CEO
Kevin Young

Kevin Young

COO

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 2 other locations
Foster City, US (HQ)
333 Lakeside Dr
Seattle, US
199 E Blaine St
Branford, US
36 E Industrial Rd
San Dimas, US
650 Cliffside Dr
Oceanside, US
4049 Avenida De La Plata
Fremont, US
7601 Dumbarton Cir

Gilead Sciences Data and Metrics

Gilead Sciences Financial Metrics

Gilead Sciences's revenue was reported to be $30.4 b in FY, 2016 which is a 7% decrease from the previous period.
USD

Revenue (FY, 2016)

30.4 b

Revenue growth (FY, 2015 - FY, 2016), %

(7%)

Gross profit (FY, 2016)

26.1 b

Gross profit margin (FY, 2016), %

86%

Net income (FY, 2016)

13.5 b

EBIT (FY, 2016)

17.6 b

Market capitalization (22-Aug-2017)

96.6 b

Cash (31-Dec-2016)

8.2 b

EV

114.7 b
Gilead Sciences's current market capitalization is $96.6 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.2 b24.9 b32.6 b30.4 b

Revenue growth, %

122%31%(7%)

Cost of goods sold

2.9 b3.8 b4 b4.3 b

Gross profit

8.3 b21.1 b28.6 b26.1 b

Gross profit Margin, %

74%85%88%86%

EBIT

4.5 b15.3 b22.2 b17.6 b

EBIT margin, %

40%61%68%58%

Pre tax profit

4.2 b14.9 b21.7 b17.1 b

Net Income

3.1 b12.1 b18.1 b13.5 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.1 b10 b12.9 b8.2 b

Inventories

2.1 b1.4 b2 b1.6 b

Current Assets

7.3 b17.7 b24.8 b20.4 b

PP&E

1.2 b1.7 b2.3 b2.9 b

Goodwill

1.2 b1.2 b1.2 b1.2 b

Total Assets

22.5 b34.7 b51.8 b57 b

Accounts Payable

1.3 b955 m1.2 b1.2 b

Total Debt

6.6 b12.4 b22.1 b26.3 b

Current Liabilities

6.3 b5.8 b9.9 b9.2 b

Additional Paid-in Capital

5.4 b2.4 b444 m454 m

Retained Earnings

6.1 b12.7 b18 b18.2 b

Total Equity

11.7 b15.8 b19.1 b19.4 b

Debt to Equity Ratio

0.6 x0.8 x1.2 x1.4 x

Debt to Assets Ratio

0.3 x0.4 x0.4 x0.5 x

Financial Leverage

1.9 x2.2 x2.7 x2.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

3.1 b12.1 b18.1 b13.5 b

Accounts Receivable

(315.3 m)(2.6 b)(1.4 b)1.2 b

Inventories

(343.1 m)143 m(855 m)(488 m)

Accounts Payable

(97.7 m)(289 m)226 m47 m

Cash From Operating Activities

3.1 b12.8 b20.3 b16.7 b

Capital Expenditures

(190.8 m)(557 m)(747 m)(748 m)

Cash From Investing Activities

(254.4 m)(1.8 b)(12.5 b)(12 b)

Cash From Financing Activities

(2.5 b)(3 b)(5 b)(9.3 b)

Interest Paid

238.3 m330 m529 m885 m

Income Taxes Paid

1.1 b2.1 b3.1 b2.4 b

Free Cash Flow

3.3 b13.4 b21.1 b17.4 b
USDY, 2016

EV/EBIT

6.5 x

EV/CFO

6.9 x

EV/FCF

6.6 x

Revenue/Employee

3.8 m

Debt/Equity

1.4 x

Debt/Assets

0.5 x

Financial Leverage

2.9 x

Gilead Sciences Operating Metrics

FY, 2016

Countries

30

Products

25

Phase III Trials

6

Phase II Trials

12

Phase I Trials

3

Facilities

5

Gilead Sciences Market Value History

Gilead Sciences Revenue Breakdown

Gilead Sciences Median Salaries

Source: 349 public H-1B filings from Gilead Sciences

Traffic Overview of Gilead Sciences

Gilead Sciences Online and Social Media Presence

Gilead Sciences Company Life and Culture

You may also be interested in